Showing results (21-30 of 74) with videos related to
Sort By:
Pageof 8
Ambio|April 27, 2013
Humans and ecosystems over the coming millennia: overview of a biosphere assessment of radioactive waste disposal in SwedenUlrik Kautsky, Tobias Lindborg, Jack ValentinLeukemia & Lymphoma|August 21, 2014
Real-world cost-effectiveness in chronic myeloid leukemia: the price of success during four decades of development from non-targeted treatment to imatinibLotta Ohm, Adam Lundqvist, Paul Dickman, et al.Experimental Hematology|February 20, 2003
Inverse relationship between myeloid maturation and leukotriene C4 synthase expression in normal and leukemic myelopoiesis-consistent overexpression of the enzyme in myeloid cells from patients with chronic myeloid leukemiaSusanne Tornhamre, Leif Stenke, Anna Granzelius, et al.Clinical Lymphoma, Myeloma & Leukemia|October 26, 2025
SOHO State of the Art Updates and Next Questions | Choosing the Best Frontline BCR::ABL1 Tyrosine Kinase Inhibitor in Chronic Myeloid Leukemia-How to Define the Treatment Value?Fadi G Haddad, Elias Jabbour, Massimo Breccia, et al.European Journal of Haematology|November 6, 2024
Loss in Overall and Quality-Adjusted Life Expectancy for Patients With Chronic-Phase Chronic Myeloid LeukemiaEnoch Yi-Tung Chen, Torsten Dahlén, Leif Stenke, et al.European Journal of Haematology|February 3, 2016
Population-based assessment of chronic myeloid leukemia in Sweden: striking increase in survival and prevalenceNiklas Gunnarsson, Fredrik Sandin, Martin Höglund, et al.Applied Health Economics and Health Policy|June 7, 2019
Cost Effectiveness of the Third-Generation Tyrosine Kinase Inhibitor (TKI) Ponatinib, vs. Second-Generation TKIs or Stem Cell Transplant, as Third-Line Treatment for Chronic-Phase Chronic Myeloid LeukemiaCarsten Hirt, Sergio Iannazzo, Silvia Chiroli, et al.Biochemical and Biophysical Research Communications|March 7, 2018
Interferon γ is a strong, STAT1-dependent direct inducer of BCL6 expression in multiple myeloma cellsDorina Ujvari, Noemi Nagy, Harsha S Madapura, et al.Plos One|January 31, 2017
Early BCR-ABL1 Transcript Decline after 1 Month of Tyrosine Kinase Inhibitor Therapy as an Indicator for Treatment Response in Chronic Myeloid LeukemiaMohamed El Missiry, Henrik Hjorth-Hansen, Johan Richter, et al.Journal of Proteome Research|May 3, 2008
Proteomic data analysis workflow for discovery of candidate biomarker peaks predictive of clinical outcome for patients with acute myeloid leukemiaJenny Forshed, Maria Pernemalm, Chuen Seng Tan, et al.Pageof 8